N-acetylcysteine versus Dopamine to Prevent Acute Kidney Injury after Cardiac Surgery in Patients with Preexisting Moderate Renal Insufficiency

Omer Faruk Savluk, Fusun Guzelmeric, Yasemin Yavuz, Deniz Cevirme, Emre Gurcu, Halide Ogus, Tulay Orki, Tuncer Kocak, Omer Faruk Savluk, Fusun Guzelmeric, Yasemin Yavuz, Deniz Cevirme, Emre Gurcu, Halide Ogus, Tulay Orki, Tuncer Kocak

Abstract

Objective: Acute kidney injury after cardiac surgery is associated with mortality and morbidity. Therefore, strategies to prevent acute kidney injury are very important. The aim of this placebo-controlled randomized double-blind study was to compare the prophylactic efficacy of N-Acetylcysteine and dopamine administration in patients with pre-existing moderate renal insufficiency who were undergoing cardiopulmonary bypass.

Methods: This study included 135 patients with pre-existing moderate renal insufficiency who were scheduled for coronary artery bypass grafting surgery. Serum creatinine and GFR were recorded preoperatively and on the first and second postoperative days.

Results: On the first and second postoperative days, the drugs used showed statistically significant differences among the creatinine groups (P<0.001). According to Tukey's HSD, on the first and second PO, the creatinine of Group N, D and P were significantly different (P<0.001). On the first and second PO, the used drugs showed statistically significant differences among the effects of eGFR (P<0.001). According to Tukey's HSD on the first postoperative day, the average eGFR score of Group N compared to D and P were significantly difference (P<0.001). On the second postoperative day, the eGFR of Group N and D showed no difference (P=0.37), but P showed a difference (P<0.001).

Conclusion: We found that the prophylactic use of intravenous N-Acetylcysteine had a protective effect on renal function, whereas the application of renal dose dopamine did not have a protective effect in patients with pre-existing moderate renal failure.

Conflict of interest statement

No conflict of interest.

Figures

Fig. 1
Fig. 1
Evolution of eGFR from first postoperative day to second postoperative day in NAC, Dopamine and Placebo Groups.
Fig. 2
Fig. 2
Evolution of creatinine from first postoperative day to second postoperative day in NAC, Dopamine and Placebo Groups.

References

    1. Thakar CV, Worley S, Arrigain S, Yared JP, Paganini EP. Influence of renal dysfunction on mortality after cardiac surgery modifying effect of preoperative renal function. Kidney Int. 2005;67(3):1112–1119.
    1. Türker H, Dönmez A, Zeyneloglu P, Sezgin A, Uluçam M. Effects of enalaprilat infusion on hemodynamics and renal function in patients undergoing cardiac surgery. Anadolu Kardiyol Derg. 2004;4(4):296–300.
    1. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006;1(1):19–32.
    1. Hollenberg NK, Adams DF, Mendell P, Abrams HL, Merrill JP. Renal vascular responses to dopamine haemodynamic and angiographic observations in normal man. Clin Sci Mol Med. 1973;45(6):733–742.
    1. Burns KE, Chu MW, Novick RJ, Fox SA, Gallo K, Martin CM. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing CABG surgery a randomized controlled trial. JAMA. 2005;294(3):342–350.
    1. Sucu N, Cinel I, Unlu A, Aytacoglu B, Tamer L, Kocak Z, et al. N-acetylcysteine for preventing pump-induced oxidoinflammatory response during cardiopulmonary bypass. Surg Today. 2004;34(3):237–242.
    1. Bakker J, Zhang H, Depierreux M, Van Asbeck S, Vincent JL. Effects of N-acetylcysteine in endotoxic shock. J Crit Care. 1994;9(4):236–243.
    1. Zhu J, Yin R, Shao H, Dong G, Luo L, Jing H. N-acetylcysteine to ameliorate acute renal injury in rat cardiopulmonary bypass model. J Thorac Cardiovasc Surg. 2007;133(3):696–703.
    1. Kelly AM, Dwamena B, Cronin P, Bernstain SJ, Carlos RC. Meta-analysis effectiveness of drugs for preventing contrast-induced neuropathy. Ann Intern Med. 2008;148(4):284–294.
    1. Fischer UM, Tossios P, Mehlhorn U. Renal protection by radical scavenging in cardiac surgery patients. Curr Med Res Opin. 2005;21(8):1161–1164.
    1. Wijeysundera DN, Beattie WS, Rao V, Granton JT, Chan CT. N-acetylcysteine for preventing acute kidney injury in cardiac surgery patients with pre-existing moderate renal insufficiency. Can J Anaesth. 2007;54(11):872–881.
    1. Sisillo E, Ceriani R, Bortone F, Juliano G, Salvi L, Veglia F, et al. N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery a prospective, randomized, clinical trial. Crit Care Med. 2008;36(1):81–86.
    1. Ayhan B, Pamuk G, Kantar B, Kanbak M, Celebioglu B, Aypar U. Renal functional effects of using N-acetylcysteine in cardiac surgery. Anesthesia J. 2012;20:159–167.
    1. Santana-Santos E, Gowdak LH, Gaiotto FA, Puig LB, Hajjar LA, Zeferino SP, et al. High dose of N-acetycysteine prevents acute kidney injury in chronic kidney disease patients undergoing myocardial revascularization. Ann Thorac Surg. 2014;97(5):1617–1623.
    1. Adabag AS, Ishani, Bloomfield HE, Ngo AK, Wilt TJ. Efficacy of N-acetylcysteine in preventing renal injury after heart surgery a systematic review of randomized trials. Eur Heart J. 2009;30(15):1910–1917.
    1. Tossios P, Bloch W, Huebner A, Raji MR, Dodos F, Klass O, et al. N-acetylcysteine prevents reactive oxygen species-mediated myocardial stress in patients undergoing cardiac surgery result of a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg. 2003;126(5):1513–1520.
    1. Borgström L, Kagedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol. 1986;31(2):217–222.
    1. Hyninen MS, Niemi TT, Pöyhiä R, Raininko EI, Salmenperä MT, Lepäntalo MJ, et al. N-acetylcysteine for the prevention of kidney injury in abdominal aortic surgery a randomized, double-blind, placebo-controlled trial. Anesth Analg. 2006;102(6):1638–1645.
    1. Haase M, Haase-Fielitz A, Bagshaw SM, Reade MC, Morgera S, Seevenayagam S, et al. Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients. Crit Care Med. 2007;35(5):1324–1331.
    1. Magder S. Reactive oxygen species toxic molecules or spark of life? Crit Care. 2006;10(1):208–208.
    1. Hoogenberg K, Smit AJ, Girbes AR. Effects of low-dose dopamine on renal and systemic hemodynamics during incremental norepinephrine infusion in healthy volunteers. Crit Care Med. 1998;26(2):260–265.
    1. Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol. 2000;11(1):97–104.
    1. Davis RF, Lappas DG, Kirklin JK, Buckley MJ, Lowenstein E. Acute oliguria after cardiopulmonary bypass renal functional improvement with low-dose dopamine infusion. Crit Care Med. 1982;10(12):852–856.
    1. Schultz MJ. N-acetylcysteine as a preventive measure for acute renal failure a plea for more accurate detection of renal function in critically ill patients. Crit Care Med. 2007;35(6):1633–1634.
    1. Bellomo R, Kellum JA, Ronco C. Defining acute renal failure physiological principles. Intensive Care Med. 2004;30(1):33–37.
    1. Bagshaw SM, Bellomo R. Early diagnosis of acute kidney injury. Curr Opin Crit Care. 2007;13(6):638–644.
    1. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality initiative workgroup Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care. 2004;8(4):R204–R212.
    1. Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15(2):407–410.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren